| Bibliographic Citation
| - Lebray Pascal, De Ledinghen Victor, Zoulim Fabien, Di Martino Vincent, Boyer Nathalie, Larrey Dominique, Botta-Fridlund Danielle, Silvain Christine, Fontaine Hélène, D'Alteroche Louis, Leroy Vincent, Bourlière Marc, Hubert-Fouchard Isabelle, Guyader Dominique, Rosa Isabelle, Nguyen-Khac Eric, Fedchuk Larysa, Akremi Raoudha, Bennai Yacia, Filipovics Anne, Zhao Yue, Bronowicki Jean-Pierre. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver International, Wiley-Blackwell, 2017, 37 (9), pp.1314 - 1324. ⟨10.1111/liv.13383⟩
- Lebray Pascal, de Ledinghen Victor, Zoulim Fabien, Di Martino Vincent, Boyer Nathalie, Larrey Dominique, Botta-Fridlund Danielle, Silvain Christine, Fontaine Hélène, d'Alteroche Louis, Leroy Vincent, Bourlière Marc, Hubert-Fouchard Isabelle, Guyader Dominique, Rosa Isabelle, Nguyen-Khac Eric, Fedchuk Larysa, Akremi Raoudha, Bennai Yacia, Filipovics Anne, Zhao Yue, Bronowicki Jean-Pierre . Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme . Liver International, 2017, 37 (9), pp.1314 - 1324 . ⟨10.1111/liv.13383⟩
- Lebray Pascal, de Ledinghen Victor, Zoulim Fabien, Di Martino Vincent, Boyer Nathalie, Larrey Dominique, Botta-Fridlund Danielle, Silvain Christine, Fontaine Hélène, d'Alteroche Louis, Leroy Vincent, Bourlière Marc, Hubert-Fouchard Isabelle, Guyader Dominique, Rosa Isabelle, Nguyen-Khac Eric, Fedchuk Larysa, Akremi Raoudha, Bennai Yacia, Filipovics Anne, Zhao Yue, Bronowicki Jean-Pierre. Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme. Liver International, 2017, 37 (9), pp.1314 - 1324. ⟨10.1111/liv.13383⟩
|
![[RDF Data]](/fct/images/sw-rdf-blue.png)
